SG11202105137RA - Application of chidamide in combination with r-chop, and drug combination - Google Patents

Application of chidamide in combination with r-chop, and drug combination

Info

Publication number
SG11202105137RA
SG11202105137RA SG11202105137RA SG11202105137RA SG11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA
Authority
SG
Singapore
Prior art keywords
combination
chidamide
chop
application
drug
Prior art date
Application number
SG11202105137RA
Other languages
English (en)
Inventor
Xianping Lu
Weili Zhao
Xin Fu
Pengpeng Xu
Ting Liu
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Rui Jin Hospital Affiliated To Shanghai Jiao Tong Univ School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd, Rui Jin Hospital Affiliated To Shanghai Jiao Tong Univ School Of Medicine filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of SG11202105137RA publication Critical patent/SG11202105137RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202105137RA 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination SG11202105137RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811394614 2018-11-20
PCT/CN2019/119170 WO2020103788A1 (zh) 2018-11-20 2019-11-18 西达本胺联合r-chop的应用及联合药物

Publications (1)

Publication Number Publication Date
SG11202105137RA true SG11202105137RA (en) 2021-06-29

Family

ID=70741744

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105137RA SG11202105137RA (en) 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination

Country Status (11)

Country Link
US (1) US12194054B2 (https=)
EP (1) EP3884943B1 (https=)
JP (1) JP7489397B2 (https=)
CN (2) CN111195249B (https=)
AU (1) AU2019385373B2 (https=)
BR (1) BR112021009627A2 (https=)
MY (1) MY209036A (https=)
PH (1) PH12021551138A1 (https=)
SG (1) SG11202105137RA (https=)
TW (1) TWI768263B (https=)
WO (1) WO2020103788A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121059617A (zh) * 2020-06-18 2025-12-05 苏州亚盛药业有限公司 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
CN112274509B (zh) * 2020-12-02 2022-04-26 四川大学华西医院 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用
CN121513004B (zh) * 2026-01-14 2026-04-03 首都医科大学附属北京友谊医院 一种治疗abc型弥漫性大b细胞淋巴瘤的组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100924737B1 (ko) * 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CN101470112A (zh) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物
CN103833626B (zh) 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
IL292457A (en) 2016-07-20 2022-06-01 Univ Columbia Histone acetyl transferase activators, their preparations and their uses
CN107157978B (zh) * 2017-05-24 2021-06-18 中国药科大学 治疗ebv+dlbcl和dlbcl的药物及组合物
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Also Published As

Publication number Publication date
JP2022511126A (ja) 2022-01-28
JP7489397B2 (ja) 2024-05-23
EP3884943C0 (en) 2024-07-17
PH12021551138A1 (en) 2022-02-21
US20220016147A1 (en) 2022-01-20
CN117797149A (zh) 2024-04-02
EP3884943A1 (en) 2021-09-29
AU2019385373B2 (en) 2025-08-21
TW202033194A (zh) 2020-09-16
EP3884943B1 (en) 2024-07-17
EP3884943A4 (en) 2022-07-06
AU2019385373A1 (en) 2021-06-24
WO2020103788A1 (zh) 2020-05-28
US12194054B2 (en) 2025-01-14
KR20210104059A (ko) 2021-08-24
TWI768263B (zh) 2022-06-21
BR112021009627A2 (pt) 2021-08-10
MY209036A (en) 2025-06-17
CA3120207A1 (en) 2020-05-28
CN111195249A (zh) 2020-05-26
CN111195249B (zh) 2023-11-28

Similar Documents

Publication Publication Date Title
ES3063733T3 (en) Pharmaceutical combination comprising tno155 and ribociclib
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
SG11202105173VA (en) Modified cell expressing therapeutic agent and uses thereof
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
LT3603620T (lt) Liposomų kompozicija ir farmacinė kompozicija
SG11202001647UA (en) Conjugate of vegf-grab protein and drug, and use thereof
PL3615035T3 (pl) Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii
DK3334760T3 (da) Antistofcysteiner med kappe og uden kappe, og deres anvendelse i antistof-lægemiddel-konjugering
IL273339A (en) Griseofulbin compound and its medical use
GB201604213D0 (en) Drug combination and its use in therapy
SG11202004529XA (en) Transformed human cell and use thereof
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
GB201820659D0 (en) Novel compostions and their use in therapy
GB201709840D0 (en) Methods and medical uses
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
PL3678692T3 (pl) Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
SG11202105137RA (en) Application of chidamide in combination with r-chop, and drug combination
HUE057073T2 (hu) Polibutadiének, azok elõállítása és alkalmazása
IL282527A (en) 5-Azaindazole history and their use
IL282526A (en) 5-Azaindazole history and their use
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
SG11201906132UA (en) Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
PL3212280T3 (pl) Dopasowanie szumu usznego u pacjentów z implantem ślimakowym (CI) i implantem słuchowym pnia mózgu (ABI)